Braun Stacey Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$218M |
| 2 |
AGN
Allergan plc
AGN
|
+$15.6M |
| 3 |
Trinity Industries
TRN
|
+$12.6M |
| 4 |
SBNY
Signature Bank
SBNY
|
+$11M |
| 5 |
Lam Research
LRCX
|
+$10.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Owens Corning
OC
|
+$12.2M |
| 2 |
Tenet Healthcare
THC
|
+$8.44M |
| 3 |
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
|
+$7.76M |
| 4 |
Cisco
CSCO
|
+$4.65M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$4.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.59% |
| 2 | Technology | 14.06% |
| 3 | Healthcare | 13.9% |
| 4 | Industrials | 11.34% |
| 5 | Consumer Discretionary | 10.37% |
Similar funds
Braun Stacey Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Braun Stacey Associates held 165 positions worth $1.75B, up 7.5% from $1.62B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Braun Stacey Associates deployed $153M of net new capital in Q4 2013, opening 17 new positions and adding to 24 existing holdings. Its largest new stake was Allergan plc: 99,951 shares worth $16.8M.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was CATAMARAN CORP COM STK (CDA), an estimated $7.76M trimmed.
- Braun Stacey Associates's largest Q4 2013 buy was Allergan plc: 99,951 shares worth $16.8M.
- Braun Stacey Associates added most to Mastercard in Q4 2013, an estimated $218M increase.
- Braun Stacey Associates's biggest Q4 2013 reduction was CATAMARAN CORP COM STK (CDA), cutting an estimated $7.76M.
- Braun Stacey Associates fully exited Owens Corning in Q4 2013, selling an estimated $12.2M.
- Braun Stacey Associates's ten largest holdings make up 17% of its $1.75B portfolio in Q4 2013.
- Braun Stacey Associates opened 17 new positions and closed 14 in Q4 2013.
- Braun Stacey Associates's portfolio value rose 7.5% quarter-over-quarter to $1.75B.
Based on Braun Stacey Associates's 13F filing for Q4 2013, filed 20 Feb 2014.